In Fight Against Lung Cancer Study Offers New Hope

Armen Hareyan's picture
Advertisement

Researchers at UCLA's Jonsson Cancer Center have discovered biomarkers that predict which patients with advanced non-small-cell lung cancer will respond to a combination treatment of the anti-inflammatory drug Celebrex and the growth factor receptor blocker Tarceva.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement